Apremilast versus methotrexate for moderate to severe plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional, early-phase study at a tertiary hospital in Peshawar will give participants with PASI ≥10 either methotrexate or apremilast and follow them for changes in skin disease severity and side effects. Clinical outcomes will include change in PASI scores and monitoring for adverse events, with particular attention to laboratory tests relevant to methotrexate (liver and blood counts) and safety signals for apremilast. The trial aims to provide head-to-head comparative data in a Pakistani population where direct comparisons are limited. Results are intended to help local clinicians balance effectiveness, tolerability, cost, and monitoring needs when choosing systemic therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.

Exclusion Criteria:

Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs

Where it's running

• MTI-HMC Peshawar
  Peshawar, Khyber Pukhtunkhwa, Pakistan Recruiting

Study contacts

• Study coordinator: Filza Ajmal, FCPS part 2
• Email: binteajmal1996@gmail.com
• Phone: +923008179226

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Roflumilast 0.3% Cream for chronic plaque psoriasis and nail psoriasis

  This study tests whether applying roflumilast 0.3% cream daily for 24 weeks helps people 12 years and older with chronic plaque psoriasis and moderate-to-severe nail psoriasis.

  Recruiting Phase 4 Modern Research Associates, PLLC · Dallas, Texas · NCT07725822

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• Intrathecal methotrexate-loaded tumor-derived vesicles for leptomeningeal lung cancer

  This treatment will try giving methotrexate-loaded tumor-derived vesicles into the spinal fluid to see if it is safe and helps adults with leptomeningeal metastasis from lung cancer who have not responded to standard treatments.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07559097

• Methotrexate in hand osteoarthritis that hasn’t improved with usual treatments

  This study tests whether methotrexate injections can help people with erosive hand OA who haven’t benefited from standard care, compared with placebo.

  Recruiting Phase 2/3 Centre Hospitalier Universitaire de Nice · Nice · NCT07501507

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.